Bupa and Quality HealthCare Medical Services Receive HKQAA ESG Connect Recognition

HONG KONG SAR –
Media OutReach Newswire – 24 June 2024 – Bupa (Asia) Limited (Bupa) and Quality HealthCare Medical Services Limited (QHMS) are proud to announce that they have been awarded the Hong Kong Quality Assurance Agency
HKQAA ESG Connect Program “Solution Providers” mark and sticker. This recognition highlights Bupa and QHMS’s exceptional performance in environmental, social, and governance (ESG) practices. Both companies have also received the
HKQAA Green and Sustainability Contribution Awards – Gold Pioneer for ESG Connect (Social), underscoring their significant contributions to the development of the ESG ecosystem.

Bupa and Quality HealthCare Medical Services receive HKQAA ESG Connect recognition

The HKQAA ESG Connect Program promotes continuous ESG development by building and nurturing the ESG Connect ecosystem. It encourages businesses to implement ESG practices, voluntarily disclose ESG initiatives, and engage with stakeholders. The HKQAA ESG Connect Program recognition signifies Bupa and QHMS’s steadfast commitment to providing ESG solutions. Through innovative and efficient campaigns and services, they aim to enhance their ESG performance and drive sustainable development across the industry and community.

“Bupa’s purpose is helping people live longer, healthier, happier lives and making a better world,” said
Fiona Harris, Managing Director of Bupa in Hong Kong. “We are immensely honoured to receive this significant accolade from the HKQAA ESG Connect Program. This acknowledges our ESG practices and inspires us to continue striving for greater contributions to society and the environment. Bupa and QHMS remain dedicated to innovation, providing sustainability solutions, and collaborating with various sectors to promote sustainable development.”

Commitment to Sustainability and Community

There is an inextricable link between our planet and our health, and delivering healthcare has a significant environmental impact. The healthcare industry must reduce its environmental footprint while protecting and regenerating the planet. Bupa and QHMS recognise the need to mitigate this impact and are actively collaborating with their partners to educate, advocate, and swiftly effect change. They contribute to the communities by engaging with local and community partners.

Bupa’s Global Initiative – Healthy Cities

Bupa’s global initiative, Healthy Cities, encourages people to become more active to protect their health and the environment. Bupa Hong Kong launched Healthy Cities in 2023, promoting step challenges among participants. Additionally, Bupa Hong Kong sponsored RunOurCity’s 2023 STREETATHON. To reinforce the connection between planetary health and physical health, Bupa Hong Kong has partnered with local start-up Clearbot on a marine waste clean-up initiative as part of its commitment to Mission Regenerate.

QHMS’s Dedication to Corporate Social Responsibility

Bupa’s healthcare division, QHMS, is deeply committed to Hong Kong and places significant emphasis on corporate social responsibility. Over the years, they have actively taken responsibility for caring for the environment and the community. In response to the ageing population and healthcare needs of the public, they organise various health volunteering services and health education programmes for the elderly and the community, raising awareness of disease prevention and demonstrating their commitment to be a healthcare partner.

The HKQAA ESG Connect mark awarded to Bupa and QHMS denotes a milestone in their leadership and ongoing contributions to the ESG field. They look forward to future collaborations with more organisations, collectively advancing long-term sustainability development and creating a better world for future generations.

Hashtag: #Bupa #QHMS #QualityHealthCare #ESG

The issuer is solely responsible for the content of this announcement.

Check Also

Top 3 Best Places to Work in Indonesia for 2024 revealed

JAKARTA, INDONESIA – Media OutReach Newswire – 19 December 2024 – Novo Nordisk, AstraZeneca, and …